RxDoctor Payments Data

Laura-Ashley O'Connell, DPM

Foot & Ankle Surgery · Upland, CANPI 1356901078

Payments from drug & device makers

$8,370in general payments, 2019–2025

Across 117 payments — averaging $71.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Evolution Surgical, Inc$1K
  • Empire Medical, Inc$1K
  • Treace Medical Concepts, Inc.$978
  • Smith+Nephew$644
  • Biotissue Holdings Inc.$398
  • plus $1K from 12 others

What the payments were for

  • Travel & lodging$7329%
  • Food & beverage$5,09161%
  • Education$2,40029%
  • Other$1472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,370 in reported general payments places this provider in the 80th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$236,808
Medicare patients
488
Services billed
3,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErtaczoSertaconazole Nitrate14$23,809
Ammonium Lactate336$6,902
Clotrimazole180$5,963
SantylCollagenase Clostridium Hist.11$4,675
Ketoconazole111$3,756
Lidocaine-PrilocaineLidocaine/Prilocaine131$1,910
Econazole Nitrate61$1,906
Terbinafine Hcl60$1,253
Ciclopirox45$1,243
Diclofenac Sodium15$1,211
Pregabalin42$765
Triamcinolone Acetonide26$661
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip12$525
Mupirocin49$430
Ibuprofen53$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$644$4,67511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →